December 7, 2022
RFA-NS-22-050 - HEAL Initiative: Discovery of Biomarkers and Biomarker Signatures to Facilitate Clinical Trials for Pain Therapeutics (UG3/UH3 Clinical Trial Optional)
National Institute of Neurological Disorders and Stroke (NINDS)
The purpose of this notice is to inform applicants of a change to the Eligibility Information for RFA-NS-22-050 "HEAL Initiative: Discovery of Biomarkers and Biomarker Signatures to Facilitate Clinical Trials for Pain Therapeutics (UG3/UH3 Clinical Trial Optional)". The Funding Opportunity Announcement (FOA) has been modified to show that "foreign components, as defined in the NIH Grants Policy Statement, are allowed. Changes to the FOA are shown below. This notice is effective for the February 23, 2023 new and resubmission application due date.
Currently Reads:
Section III. Elgibility Information
1. Eligible Applicants
Foreign Institutions
Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Modified to Read:
Section III. Eligibility Information
1. Eligible Applicants
Foreign Institutions
Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
All other aspects of this FOA remain unchanged.
Ram Arudchandran, PhD
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-402-5257
Email: [email protected]
and Human Services (HHS)
